1
|
He W, Tang H, Li J, Shen X, Zhang X, Li C, Liu H, Yu W. Using the coefficient of determination to identify injury regions after stroke in pre-clinical FDG-PET images. Comput Biol Med 2025; 184:109401. [PMID: 39591668 DOI: 10.1016/j.compbiomed.2024.109401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Revised: 11/05/2024] [Accepted: 11/07/2024] [Indexed: 11/28/2024]
Abstract
BACKGROUND In the analysis of brain fluorodeoxyglucose positron emission tomography (FDG-PET) images, intensity normalization is a necessary step to reduce inter-subject variability. However, the choice of the most appropriate normalization method in stroke studies remains unclear, as demonstrated by inconsistent findings in the literature. MATERIALS AND METHODS Here, we propose a regression- and single-subject-based model for analyzing FDG-PET images without intensity normalization. Two independent data sets were collected before and after middle cerebral artery occlusion (MCAO), with one comprising 120 rats and the other 96 rats. After data preprocessing, voxel intensities in the same region and hemisphere were paired before and after the MCAO scan. A linear regression model was applied to the paired data, and the coefficient of determination R2 was calculated to measure the linearity. The R2 values between the ipsilateral and contralateral hemispheres were compared, and significant regions were defined as those with reduced linearity. Our method was compared with voxel-wise analysis under different intensity normalization methods and validated using the triphenyl tetrazolium chloride (TTC) staining data. RESULTS The significant regions identified by the proposed method showed a large degree of overlap with the infarcted regions identified by TTC data, as measured by the Dice similarity coefficient (DSC). The average DSC of the proposed method was 59.7%, whereas the DSCs of the existing approaches ranged from 41.4%∼51.3%. Additional validation using receiver operating characteristic (ROC) demonstrated that the area under the curve (AUC) of the average ROC curves reached 0.84 using the proposed method, whereas existing methods achieved AUCs ranging from 0.77∼0.79. The identified regions were consistent across the two independent data sets, and some findings were corroborated by other publications. CONCLUSIONS The proposed model presents a novel quantitative approach for identifying injury regions post-stroke using FDG-PET images. The calculation does not require intensity normalization and can be applied to individual subjects. The method yields more sensitive results compared to existing identification methods.
Collapse
Affiliation(s)
- Wuxian He
- Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
| | - Hongtu Tang
- Department of Acupuncture and Moxibustion, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei, China
| | - Jia Li
- Xianning Hospital of Traditional Chinese Medicine, Xianning, 437100, Hubei, China
| | - Xiaoyan Shen
- College of Science, Zhejiang University of Technology, Hangzhou, 310023, Zhejiang, China
| | - Xuechen Zhang
- Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
| | - Chenrui Li
- Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China
| | - Huafeng Liu
- State Key Laboratory of Modern Optical Instrumentation, College of Optical Science and Engineering, Zhejiang University, 310027, Zhejiang, China
| | - Weichuan Yu
- Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China; HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen, China.
| |
Collapse
|
2
|
Rey-Bretal D, García-Varela L, Gómez-Lado N, Moscoso A, Piñeiro-Fiel M, Díaz-Platas L, Medin S, Fernández-Ferreiro A, Ruibal Á, Sobrino T, Silva-Rodríguez J, Aguiar P. Quantitative brain [ 18F]FDG PET beyond normal blood glucose levels. Neuroimage 2024; 300:120873. [PMID: 39341474 DOI: 10.1016/j.neuroimage.2024.120873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2024] [Revised: 09/17/2024] [Accepted: 09/25/2024] [Indexed: 10/01/2024] Open
Abstract
Introduction SUV measurements from static brain [18F]FDG PET acquisitions are a commonly used tool in preclinical research, providing a simple alternative for kinetic modelling, which requires complex and time-consuming dynamic acquisitions. However, SUV can be severely affected by the animal handling and preconditioning protocols, primarily by those that may induce changes in blood glucose levels (BGL). Here, we aimed at developing and investigating the feasibility of SUV-based approaches for a wide range of BGL far beyond normal values, and consequently, to develop and validate a new model to generate standardized and reproducible SUV measurements for any BGL. Material and methods We performed dynamic and static brain [18F]FDG PET acquisitions in 52 male Sprague-Dawley rats sorted into control (n = 10), non-fasting (n = 14), insulin-induced hypoglycemia (n = 12) and glucagon-induced hyperglycemia (n = 16) groups. Brain [18F]FDG PET images were cropped, aligned and co-registered to a standard template to calculate whole-brain and regional SUV. Cerebral Metabolic Rate of Glucose (CMRglc) was also estimated from 2-Tissue Compartment Model (2TCM) and Patlak plot for validation purposes. Results Our results showed that BGL=100±6 mg/dL can be considered a reproducible reference value for normoglycemia. Furthermore, we successfully established a 2nd-degree polynomial model (C1=0.66E-4, C2=-0.0408 and C3=7.298) relying exclusively on BGL measures at pre-[18F]FDG injection time, that characterizes more precisely the relationship between SUV and BGL for a wide range of BGL values (from 10 to 338 mg/dL). We confirmed the ability of this model to generate corrected SUV estimations that are highly correlated to CMRglc estimations (R2= 0.54 2TCM CMRgluc and R2= 0.49 Patlak CMRgluc). Besides, slight regional differences in SUV were found in animals from extreme BGL groups, showing that [18F]FDG uptake is mostly directed toward central regions of the brain when BGLs are significantly decreased. Conclusion Our study successfully established a non-linear model that relies exclusively on pre-scan BGL measurements to characterize the relationship between [18F]FDG SUV and BGL. The extensive validation confirmed its ability to generate SUV-based surrogates of CMRglu along a wide range of BGL and it holds the potential to be adopted as a standard protocol by the preclinical neuroimaging community using brain [18F]FDG PET imaging.
Collapse
Affiliation(s)
- David Rey-Bretal
- Molecular Imaging Biomarkers Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Biomarkers Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Lara García-Varela
- Molecular Imaging Biomarkers Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Biomarkers Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Noemí Gómez-Lado
- Molecular Imaging Biomarkers Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Biomarkers Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Alexis Moscoso
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden
| | - Manuel Piñeiro-Fiel
- Molecular Imaging Biomarkers Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Biomarkers Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Lucía Díaz-Platas
- Galician PET Radiopharmacy Unit, GALARIA, University Clinical Hospital, Santiago de Compostela, Spain
| | - Santiago Medin
- Galician PET Radiopharmacy Unit, GALARIA, University Clinical Hospital, Santiago de Compostela, Spain
| | - Anxo Fernández-Ferreiro
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; FarmaCHUS Lab, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Álvaro Ruibal
- Molecular Imaging Biomarkers Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Biomarkers Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Tomás Sobrino
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain; NeuroAging Laboratory Group (NEURAL), Clinical Neurosciences Research Laboratories (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Jesús Silva-Rodríguez
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain; Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII, Madrid, Spain.
| | - Pablo Aguiar
- Molecular Imaging Biomarkers Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Biomarkers Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
3
|
Doyen M, Lambert C, Roeder E, Boutley H, Chen B, Pierson J, Verger A, Raffo E, Karcher G, Marie PY, Maskali F. Assessment of a one-week ketogenic diet on brain glycolytic metabolism and on the status epilepticus stage of a lithium-pilocarpine rat model. Sci Rep 2024; 14:5063. [PMID: 38424459 PMCID: PMC10904769 DOI: 10.1038/s41598-024-53824-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 02/05/2024] [Indexed: 03/02/2024] Open
Abstract
The ketogenic diet (KD) has been shown to be effective in refractory epilepsy after long-term administration. However, its interference with short-term brain metabolism and its involvement in the early process leading to epilepsy remain poorly understood. This study aimed to assess the effect of a short-term ketogenic diet on cerebral glucose metabolic changes, before and after status epilepticus (SE) in rats, by using [18F]-FDG PET. Thirty-nine rats were subjected to a one-week KD (KD-rats, n = 24) or to a standard diet (SD-rats, n = 15) before the induction of a status epilepticus (SE) by lithium-pilocarpine administrations. Brain [18F]-FDG PET scans were performed before and 4 h after this induction. Morphological MRIs were acquired and used to spatially normalize the PET images which were then analyzed voxel-wisely using a statistical parametric-based method. Twenty-six rats were analyzed (KD-rats, n = 15; SD-rats, n = 11). The 7 days of the KD were associated with significant increases in the plasma β-hydroxybutyrate level, but with an unchanged glycemia. The PET images, recorded after the KD and before SE induction, showed an increased metabolism within sites involved in the appetitive behaviors: hypothalamic areas and periaqueductal gray, whereas no area of decreased metabolism was observed. At the 4th hour following the SE induction, large metabolism increases were observed in the KD- and SD-rats in areas known to be involved in the epileptogenesis process late-i.e., the hippocampus, parahippocampic, thalamic and hypothalamic areas, the periaqueductal gray, and the limbic structures (and in the motor cortex for the KD-rats only). However, no statistically significant difference was observed when comparing SD and KD groups at the 4th hour following the SE induction. A one-week ketogenic diet does not prevent the status epilepticus (SE) and associated metabolic brain abnormalities in the lithium-pilocarpine rat model. Further explorations are needed to determine whether a significant prevention could be achieved by more prolonged ketogenic diets and by testing this diet in less severe experimental models, and moreover, to analyze the diet effects on the later and chronic stages leading to epileptogenesis.
Collapse
Affiliation(s)
- Matthieu Doyen
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France.
- Lorraine University, IADI, INSERM UMR 1254, 54000, Nancy, France.
| | - Clémentine Lambert
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
- Department of Neuropediatrics, Children's Hospital CHRU Nancy, 54000, Nancy, France
| | - Emilie Roeder
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
| | - Henri Boutley
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
| | - Bailiang Chen
- CHRU-Nancy, INSERM UMR 1433, CIC, Innovation Technologique, Université de Lorraine, 54000, Nancy, France
| | - Julien Pierson
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
| | - Antoine Verger
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
- Lorraine University, IADI, INSERM UMR 1254, 54000, Nancy, France
- Department of Nuclear Medicine, University Hospital, 54000, Nancy, France
| | - Emmanuel Raffo
- Department of Neuropediatrics, Children's Hospital CHRU Nancy, 54000, Nancy, France
| | - Gilles Karcher
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
- Department of Nuclear Medicine, University Hospital, 54000, Nancy, France
| | - Pierre-Yves Marie
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
- Lorraine University, IADI, INSERM UMR 1254, 54000, Nancy, France
- Department of Nuclear Medicine, University Hospital, 54000, Nancy, France
| | - Fatiha Maskali
- NANCYCLOTEP-Molecular and Experimental Imaging Platform, 54000, Nancy, France
- Lorraine University, INSERM DCAC1116, 54000, Nancy, France
| |
Collapse
|
4
|
Kong Z, Li Z, Chen J, Shi Y, Li N, Ma W, Wang Y, Yang Z, Liu Z. A histogram of [ 18F]BBPA PET imaging differentiates non-neoplastic lesions from malignant brain tumors. EJNMMI Res 2024; 14:12. [PMID: 38305994 PMCID: PMC10837405 DOI: 10.1186/s13550-024-01069-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 01/22/2024] [Indexed: 02/03/2024] Open
Affiliation(s)
- Ziren Kong
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Zhu Li
- Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China
| | - Junyi Chen
- National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, BeijingBeijing, China
| | - Yixin Shi
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Nan Li
- Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China
| | - Wenbin Ma
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yu Wang
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| | - Zhi Yang
- Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
| | - Zhibo Liu
- Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
- National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, BeijingBeijing, China.
- Peking University-Tsinghua University Center for Life Sciences, Beijing, China.
- Changping Laboratory, Beijing, China.
| |
Collapse
|
5
|
Nowell J, Raza S, Livingston NR, Sivanathan S, Gentleman S, Edison P. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory? J Alzheimers Dis 2024; 101:987-999. [PMID: 39302365 DOI: 10.3233/jad-240434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2024]
Abstract
Background Tau aggregation demonstrates close associations with hypometabolism in Alzheimer's disease (AD), although differing pathophysiological processes may underlie their development. Objective To establish whether tau deposition and glucose metabolism have different trajectories in AD progression and evaluate the utility of global measures of these pathological hallmarks in predicting cognitive deficits. Methods 279 participants with amyloid-β (Aβ) status, and T1-weighted MRI scans, were selected from the Alzheimer's Disease Neuroimaging Initiative (http://adni.loni.usc.edu). We created the standard uptake value ratio images using Statistical Parametric Mapping 12 for [18F]AV1451-PET (tau) and [18F]FDG-PET (glucose metabolism) scans. Voxel-wise group and single-subject level SPM analysis evaluated the relationship between global [18F]FDG-PET and [18F]AV1451-PET depending on the Aβ status. Linear models assessed whether tau deposition or glucose metabolism better predicted clinical progression. Results There was a dissociation between global cerebral glucose hypometabolism and global tau load in amyloid-positive AD and amyloid-negative mild cognitive impairment (MCI) (p > 0.05). Global hypometabolism was only associated with global cortical tau in amyloid-positive MCI. Voxel-level single subject tau load better predicted neuropsychological performance, Alzheimer's disease assessment scale-cognitive (ADAS-Cog) 13 score, and one-year change compared with regional and global hypometabolism. Conclusions A dissociation between tau pathology and glucose metabolism at a global level in AD could imply that other pathological processes influence glucose metabolism. Furthermore, as tau is a better predictor of clinical progression, these processes may have independent trajectories and require independent consideration in the context of therapeutic interventions.
Collapse
Affiliation(s)
- Joseph Nowell
- Department of Brain Sciences, Division of Neurology, Faculty of Medicine, Imperial College London, London, UK
| | - Sanara Raza
- Department of Brain Sciences, Division of Neurology, Faculty of Medicine, Imperial College London, London, UK
| | - Nicholas R Livingston
- Department of Brain Sciences, Division of Neurology, Faculty of Medicine, Imperial College London, London, UK
| | - Shayndhan Sivanathan
- Department of Brain Sciences, Division of Neurology, Faculty of Medicine, Imperial College London, London, UK
| | - Steve Gentleman
- Department of Brain Sciences, Division of Neurology, Faculty of Medicine, Imperial College London, London, UK
| | - Paul Edison
- Department of Brain Sciences, Division of Neurology, Faculty of Medicine, Imperial College London, London, UK
- School of Medicine, Cardiff University, Cardiff, Wales, UK
| |
Collapse
|
6
|
Pan D, Xu Y, Wang X, Wang L, Yan J, Shi D, Yang M, Chen M. Evaluation the in vivo behaviors of PM 2.5 in rats using noninvasive PET imaging with mimic particles. CHEMOSPHERE 2023; 339:139663. [PMID: 37506893 DOI: 10.1016/j.chemosphere.2023.139663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 07/20/2023] [Accepted: 07/25/2023] [Indexed: 07/30/2023]
Abstract
Inhaled PM2.5 particles is harmful to human health. However, real-time tracking of PM2.5 particles and dynamic evaluation of the pharmacokinetic behaviors in vivo are still challenging. Here, PET imaging is utilized to noninvasively monitor the in vivo behavior of PM2.5 particles in rats. To mimic aerosol PM2.5 particles suspended in ambient air, 89Zr-labeled melanin nanoparticles (89Zr-MNP) are nebulized into microscopic liquid particles with a mean size of 2.5 μm. Then, the 89Zr-labeled PM2.5 mimic particles (89Zr-PM2.5) are administrated into rats via inhalation. PET imaging showed that 89Zr-PM2.5 mainly accumulated in the lungs for up to 384 h after administration. Besides, we also observe that a small amount of 89Zr-PM2.5 can penetrate the brain through the inhalation. Further PET imaging showed that enhanced uptakes of 18F-FDG and 18F-DPA-714 were found in the brain of rats upon PM2.5 mimic particle exposure, which revealed that pulmonary exposure to PM2.5 could cause potential damages to the brain. Note that abnormal glucose metabolism was reversed, but the neuroinflammation was permanent and could not be alleviated after ceasing PM2.5 exposure. Our results demonstrate that PET is a sensitive and feasible tool for evaluating the in vivo behaviors of PM2.5.
Collapse
Affiliation(s)
- Donghui Pan
- Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, 214122, China; Key Laboratory of Nuclear Medicine, National Health Commission, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China
| | - Yuping Xu
- Key Laboratory of Nuclear Medicine, National Health Commission, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China
| | - Xinyu Wang
- Key Laboratory of Nuclear Medicine, National Health Commission, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China
| | - Lizhen Wang
- Key Laboratory of Nuclear Medicine, National Health Commission, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China
| | - Junjie Yan
- Key Laboratory of Nuclear Medicine, National Health Commission, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China
| | - Dongjian Shi
- Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, 214122, China
| | - Min Yang
- Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, 214122, China; Key Laboratory of Nuclear Medicine, National Health Commission, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
| | - Mingqing Chen
- Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, 214122, China.
| |
Collapse
|
7
|
Bøgh N, Gordon JW, Hansen ESS, Bok RA, Blicher JU, Hu JY, Larson PEZ, Vigneron DB, Laustsen C. Initial Experience on Hyperpolarized [1- 13C]Pyruvate MRI Multicenter Reproducibility-Are Multicenter Trials Feasible? Tomography 2022; 8:585-595. [PMID: 35314625 PMCID: PMC8938827 DOI: 10.3390/tomography8020048] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 02/17/2022] [Accepted: 02/18/2022] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Magnetic resonance imaging (MRI) with hyperpolarized [1-13C]pyruvate allows real-time and pathway specific clinical detection of otherwise unimageable in vivo metabolism. However, the comparability between sites and protocols is unknown. Here, we provide initial experiences on the agreement of hyperpolarized MRI between sites and protocols by repeated imaging of same healthy volunteers in Europe and the US. METHODS Three healthy volunteers traveled for repeated multicenter brain MRI exams with hyperpolarized [1-13C]pyruvate within one year. First, multisite agreement was assessed with the same echo-planar imaging protocol at both sites. Then, this was compared to a variable resolution echo-planar imaging protocol. In total, 12 examinations were performed. Common metrics of 13C-pyruvate to 13C-lactate conversion were calculated, including the kPL, a model-based kinetic rate constant, and its model-free equivalents. Repeatability was evaluated with intraclass correlation coefficients (ICC) for absolute agreement computed using two-way random effects models. RESULTS The mean kPL across all examinations in the multisite comparison was 0.024 ± 0.0016 s-1. The ICC of the kPL was 0.83 (p = 0.14) between sites and 0.7 (p = 0.09) between examinations of the same volunteer at any of the two sites. For the model-free metrics, the lactate Z-score had similar site-to-site ICC, while it was considerably lower for the lactate-to-pyruvate ratio. CONCLUSIONS Estimation of metabolic conversion from hyperpolarized [1-13C]pyruvate to lactate using model-based metrics such as kPL suggests close agreement between sites and examinations in volunteers. Our initial results support harmonization of protocols, support multicenter studies, and inform their design.
Collapse
Affiliation(s)
- Nikolaj Bøgh
- The MR Research Center, Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark; (E.S.S.H.); (C.L.)
| | - Jeremy W. Gordon
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94158, USA; (J.W.G.); (R.A.B.); (J.Y.H.); (P.E.Z.L.); (D.B.V.)
| | - Esben S. S. Hansen
- The MR Research Center, Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark; (E.S.S.H.); (C.L.)
| | - Robert A. Bok
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94158, USA; (J.W.G.); (R.A.B.); (J.Y.H.); (P.E.Z.L.); (D.B.V.)
| | - Jakob U. Blicher
- Center of Functionally Integrative Neuroscience, Aarhus University, 8000 Aarhus, Denmark;
| | - Jasmine Y. Hu
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94158, USA; (J.W.G.); (R.A.B.); (J.Y.H.); (P.E.Z.L.); (D.B.V.)
- UC Berkeley—UCSF Graduate Program in Bioengineering, University of California San Francisco and University of California, Berkeley, CA 94720, USA
| | - Peder E. Z. Larson
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94158, USA; (J.W.G.); (R.A.B.); (J.Y.H.); (P.E.Z.L.); (D.B.V.)
- UC Berkeley—UCSF Graduate Program in Bioengineering, University of California San Francisco and University of California, Berkeley, CA 94720, USA
| | - Daniel B. Vigneron
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94158, USA; (J.W.G.); (R.A.B.); (J.Y.H.); (P.E.Z.L.); (D.B.V.)
- UC Berkeley—UCSF Graduate Program in Bioengineering, University of California San Francisco and University of California, Berkeley, CA 94720, USA
| | - Christoffer Laustsen
- The MR Research Center, Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark; (E.S.S.H.); (C.L.)
| |
Collapse
|